127 related articles for article (PubMed ID: 34633894)
41. Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
Meijer D; Luiting HB; van Leeuwen PJ; Remmers S; Jansen BHE; Bodar YJL; Witteveen T; Schaake EE; van der Poel HG; Wondergem M; Busstra MB; Nieuwenhuijzen JA; Meijnen P; Brabander T; van Moorselaar RJA; Hendrikse NH; Oprea-Lager DE; Roobol MJ; Vis AN
J Urol; 2021 Apr; 205(4):1100-1109. PubMed ID: 33207138
[TBL] [Abstract][Full Text] [Related]
42. Impact of
Jani AB; Schreibmann E; Rossi PJ; Shelton J; Godette K; Nieh P; Master VA; Kucuk O; Goodman M; Halkar R; Cooper S; Chen Z; Schuster DM
J Nucl Med; 2017 Mar; 58(3):412-418. PubMed ID: 27609792
[TBL] [Abstract][Full Text] [Related]
43. Intensity-modulated salvage radiotherapy with simultaneous integrated boost for local recurrence of prostate carcinoma: a pilot study on the place of PET-choline for guiding target volume delineation.
Wahart A; Guy JB; Vallard A; Geissler B; Ben Mrad M; Falk AT; Prevot N; de Laroche G; Rancoule C; Chargari C; Magné N
Br J Radiol; 2016; 89(1058):20150579. PubMed ID: 26648528
[TBL] [Abstract][Full Text] [Related]
44. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?
Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H
Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339
[TBL] [Abstract][Full Text] [Related]
45. PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy.
Wenzel M; Hussein R; Maurer T; Karakiewicz PI; Tilki D; Graefen M; Würnschimmel C
Urol Oncol; 2022 Jan; 40(1):7.e1-7.e8. PubMed ID: 34340868
[TBL] [Abstract][Full Text] [Related]
46. Utility of
Wang Y; Chow DZ; Ebert E; Tajmir S; Scott JA; Palmer EL
AJR Am J Roentgenol; 2020 Oct; 215(4):997-1001. PubMed ID: 32569513
[No Abstract] [Full Text] [Related]
47. Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
Linxweiler J; Sprenk J; Cascetta K; Pryalukhin A; Hölters S; Zeuschner P; Nini A; Al-Kailani Z; Ezziddin S; Bohle RM; Fries P; Ohlmann CH; Heinzelbecker J; Siemer S; Stöckle M; Junker K; Saar M
J Urol; 2021 Jul; 206(1):88-96. PubMed ID: 33617326
[TBL] [Abstract][Full Text] [Related]
48. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol; 2020 Dec; 78(6):779-782. PubMed ID: 32624281
[TBL] [Abstract][Full Text] [Related]
49. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
[TBL] [Abstract][Full Text] [Related]
50. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.
De Bari B; Mazzola R; Aiello D; Fersino S; Gregucci F; Alongi P; Nicodemo M; Cavalleri S; Salgarello M; Alongi F
Radiol Med; 2018 Sep; 123(9):719-725. PubMed ID: 29687208
[TBL] [Abstract][Full Text] [Related]
51. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G
Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076
[TBL] [Abstract][Full Text] [Related]
52. Randomized Trial of Conventional Versus Conventional Plus Fluciclovine (
Dhere VR; Schuster DM; Goyal S; Schreibmann E; Hershatter BW; Rossi PJ; Shelton JW; Patel PR; Jani AB
Int J Radiat Oncol Biol Phys; 2022 Aug; 113(5):1003-1014. PubMed ID: 35417762
[TBL] [Abstract][Full Text] [Related]
53.
Bowden P; See AW; So K; Lawrentschuk N; Moon D; Murphy DG; Rao R; Crosthwaite A; King D; Haxhimolla H; Grummet J; Ruljancich P; Gyomber D; Landau A; Campbell N; Frydenberg M; Smyth LML; Nolan S; Gwini SM; McKenzie DP
World J Urol; 2021 Nov; 39(11):4117-4125. PubMed ID: 34076753
[TBL] [Abstract][Full Text] [Related]
54. Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on
Abiodun-Ojo OA; Jani AB; Akintayo AA; Akin-Akintayo OO; Odewole OA; Tade FI; Joshi SS; Master VA; Fielder B; Halkar RK; Zhang C; Goyal S; Goodman MM; Schuster DM
J Nucl Med; 2021 Aug; 62(8):1089-1096. PubMed ID: 33517323
[TBL] [Abstract][Full Text] [Related]
55. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
56.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
57. Prospective evaluation of fluciclovine (
Akin-Akintayo O; Tade F; Mittal P; Moreno C; Nieh PT; Rossi P; Patil D; Halkar R; Fei B; Master V; Jani AB; Kitajima H; Osunkoya AO; Ormenisan-Gherasim C; Goodman MM; Schuster DM
Eur J Radiol; 2018 May; 102():1-8. PubMed ID: 29685521
[TBL] [Abstract][Full Text] [Related]
58. Usefulness of
López Rodríguez E; Tirado Hospital JL; Álvarez Pérez RM; Gómez Izquierdo L; Jiménez-Hoyuela JM
Actas Urol Esp (Engl Ed); 2020; 44(6):437-443. PubMed ID: 32576406
[TBL] [Abstract][Full Text] [Related]
59. Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy.
Luiting HB; van Leeuwen PJ; Remmers S; Donswijk M; Busstra MB; Bakker IL; Brabander T; Stokkel M; van der Poel HG; Roobol MJ
J Urol; 2020 Sep; 204(3):503-510. PubMed ID: 32149575
[TBL] [Abstract][Full Text] [Related]
60. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
Marcus C; Butler P; Bagrodia A; Cole S; Subramaniam RM
AJR Am J Roentgenol; 2020 Aug; 215(2):267-276. PubMed ID: 32551903
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
